期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 61, 期 3, 页码 843-866出版社
IOS PRESS
DOI: 10.3233/JAD-170512
关键词
Alzheimer's disease; amyloid-beta; amyloid-beta protein precursor; curcumin; mitochondria; oxidative stress; reactive oxygen species
资金
- National Institutes of Health [AG042178, AG47812, NS105473]
- Garrison Family Foundation
- Sex and Gender Alzheimer's Association (SAGA)
- Alzheimer's Association [2016-NIRG-39787]
- Center of Excellence for Translational Neuroscience and Therapeutics [PN-CTNT20115-AR]
- SAGA
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS105473] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG042178, R01AG047812] Funding Source: NIH RePORTER
The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-beta (A beta)-induced toxicity in Alzheimer's disease (AD) pathogenesis. Natural products, such as ginger, curcumin, and gingko biloba have been used as diets and dietary supplements to treat human diseases, including cancer, cardiovascular, respiratory, infectious, diabetes, obesity, metabolic syndromes, and neurological disorders. Products derived from plants are known to have protective effects, including anti-inflammatory, antioxidant, anti-arthritis, pro-healing, and boosting memory cognitive functions. In the last decade, several groups have designed and synthesized curcumin and its derivatives and extensively tested using cell and mouse models of AD. Recent research on A beta and curcumin has revealed that curcumin prevents A beta aggregation and crosses the blood-brain barrier, reach brain cells, and protect neurons from various toxic insults of aging and A beta in humans. Recent research has also reported that curcumin ameliorates cognitive decline and improves synaptic functions in mouse models of AD. Further, recent groups have initiated studies on elderly individuals and patients with AD and the outcome of these studies is currently being assessed. This article highlights the beneficial effects of curcumin on AD. This article also critically assesses the current limitations of curcumin's bioavailability and urgent need for new formulations to increase its brain levels to treat patients with AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据